Stem Cell Infusion Cut Fractures; Testosterone for Menopause; BMD and Cognition
[post_content]
Disclaimer: This article has been automatically aggregated from
A single stem cell infusion led to a 94% reduction in fragility fractures over 2 years in a small study of 10 women with advanced osteoporosis. (Cell)
Novo Nordisk’s low-dose investigational CagriSema outperformed tirzepatide (Mounjaro) 5 mg for weight loss (12.4% vs 9.1%) in a phase III trial of adults with type 2 diabetes.
Meanwhile, Roche’s investigational dual agonist enicepatide led to a 15.5% weight loss at 48 weeks in a phase II trial of adults with obesity and diabetes.
The FDA convened an expert panel last week to evaluate the evidence for testosterone therapy for menopausal women.
After a brief pause, the Pentagon will continue its controversial program to test troops’ testosterone levels. (Reuters via AOL)
Deep learning analysis of noncontrast chest CTs linked lower thoracic vertebral bone mineral density (BMD) with faster cognitive decline, particularly in adults with diabetes. (Radiology)
The Justice Department announced that New York University Langone Hospitals and the University of Pittsburgh Medical Center agreed to stop providing gender-affirming care for minors and to pay over $9 million combined in fines.
Dozens of patients have sued GLP-1 drug manufacturers, claiming they were not adequately warned about the risk of non-arteritic anterior ischemic optic neuropathy, a rare type of sudden vision loss. (ABC News)
The Endocrine Society announced the 13 winners of its 2027 Laureate Awards.
Employer-sponsored health insurance plans are expected to adjust their coverage of GLP-1 drugs. (Washington Post)
A real-world study of 246 adults with type 1 diabetes linked worsening time-in-target glucose range to a higher 5-year incidence of microvascular complications. (Journal of Clinical Endocrinology & Metabolism)
Illinois Gov. JB Pritzker (D), who has diabetes and long struggled with his weight, said he lost 80 pounds after using a GLP-1 medication. (People)
SGLT2 inhibitors and GLP-1 drugs significantly reduced the risk of renal function decline compared with DPP-4 inhibitors in a target trial emulation of adults with type 2 diabetes and albuminuria. (The BMJ)
for informational purposes only. We do not claim ownership, accuracy, or liability for the content provided. All rights belong to the original publisher.